Enterprise Value

1.747B

Cash

252.5M

Avg Qtr Burn

-54.1M

Short % of Float

7.54%

Insider Ownership

17.70%

Institutional Own.

73.77%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INBRX-101 (AAT-Fc fusion protein) Details
Severe alpha-1 antitrypsin deficiency, Genetic disorder, Rare genetic disease, Emphysema due to Alpha-1 Antitrypsin Deficiency

Phase 2

Data readout

INBRX-109 (DR5 agonist) Details
Solid tumor/s, Cancer, Chondrosarcoma

Phase 2

Data readout

INBRX-109 (DR5 agonist) Details
Relapsed/refractory Ewing sarcoma

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued